KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis.Muscle NervePMID 34890069PMC93051132022-Mar0.98未发现恶性肿瘤人群证据。待处理
Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain compared with leuprorelin in Japanese women: a phase 3, randomized, double-blind, noninferiority study.Fertil SterilPMID 34895700无 PMCID2022-Mar0.98未发现恶性肿瘤人群证据。待处理
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.Ann OncolPMID 34921960PMC94477922022-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.Lancet Respir MedPMID 34942085无 PMCID2022-Mar0.98未发现恶性肿瘤人群证据。待处理
Efficacy of Zoledronic Acid in the Treatment of Nonmalignant Painful Bone Marrow Lesions: A Triple-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial (ZoMARS).J Bone Miner ResPMID 34954857无 PMCID2022-Mar0.98未发现恶性肿瘤人群证据。待处理
Iron serum levels and iron homeostasis parameters in patients with nosocomial pneumonia treated with cefiderocol: post hoc analysis of the APEKS-NP study.Eur J Clin Microbiol Infect DisPMID 35025025PMC88313522022-Mar0.98未发现恶性肿瘤人群证据。待处理
Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49.Dig Liver DisPMID 35027324无 PMCID2022-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Does baseline quality of life predict the occurrence of complications in resectable esophageal cancer?Surg OncolPMID 35030410无 PMCID2022-Mar0.95The record describes an original Phase III randomized trial in human esophageal cancer with time-to-event endpoints, but the intervention is surgical (hybrid vs. open esophagectomy) without a drug-containing arm. It is a secondary analysis of baseline quality of life as a prognostic factor for complications and survival, not a primary drug efficacy report.待处理
Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER).Clin Drug InvestigPMID 35041159PMC89309392022-Mar0.98未发现恶性肿瘤人群证据。待处理
Groups 4 Health versus cognitive-behavioural therapy for depression and loneliness in young people: randomised phase 3 non-inferiority trial with 12-month follow-up.Br J PsychiatryPMID 35049477无 PMCID2022-Mar0.98未发现恶性肿瘤人群证据。待处理
Sustained seizure freedom with adjunctive perampanel in patients with convulsive seizures: Post hoc analysis of open-label extension studies 307 and 332.Epilepsy BehavPMID 35078116无 PMCID2022-Mar0.98未发现恶性肿瘤人群证据。待处理
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.Lancet Diabetes EndocrinolPMID 35131037无 PMCID2022-Mar0.98未发现恶性肿瘤人群证据。待处理
Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2.Clin TherPMID 35131090无 PMCID2022-Mar0.98未发现恶性肿瘤人群证据。待处理
Randomized Pharmacokinetic Study of a Highly Purified Human Chorionic Gonadotropin and of a Recombinant Human Chorionic Gonadotropin Following Single Subcutaneous Administration in Healthy Women.Clin Drug InvestigPMID 35137345PMC89309022022-Mar0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial.Lancet PsychiatryPMID 35151410无 PMCID2022-Mar0.98未发现恶性肿瘤人群证据。待处理
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.Lancet OncolPMID 35151415无 PMCID2022-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Weight change during the first week of life and a new method for retrospective prediction of birthweight among exclusively breastfed newborns.Acta Obstet Gynecol ScandPMID 35156190PMC95644502022-Mar0.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of HSK3486 for Anesthesia/Sedation in Patients Undergoing Fiberoptic Bronchoscopy: A Multicenter, Double-Blind, Propofol-Controlled, Randomized, Phase 3 Study.CNS DrugsPMID 35157236PMC89270142022-Mar0.98未发现恶性肿瘤人群证据。待处理
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.Lancet OncolPMID 35157830无 PMCID2022-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet HaematolPMID 35240074无 PMCID2022-Mar0.95The record is a Phase III randomized trial of a drug for chemotherapy-induced thrombocytopenia in cancer patients. However, the primary efficacy endpoint is a composite proportion of responders (not requiring platelet transfusion or dose reduction/delay), not a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, or TTP. The report lacks Kaplan-Meier survival analysis or hazard ratios for a time-to-event outcome. Therefore, it does not meet the required criteria for inclusion in the Kaplan-Meier digitization cohort.待处理
Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy.RMD OpenPMID 35264432PMC89153622022-Mar0.98未发现恶性肿瘤人群证据。待处理
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.NaturePMID 35322232PMC89677132022-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study.JCO Glob OncolPMID 35324270PMC90712532022-Mar0.95The study is a randomized, Phase III trial with a drug intervention (biosimilar vs. originator pegfilgrastim) in oncology, but its primary efficacy endpoint is the duration of severe neutropenia (DSN), a continuous outcome, not a time-to-event endpoint. The secondary endpoints are also incidence-based or categorical measures (e.g., incidence of severe neutropenia, febrile neutropenia, infections) and are not reported as time-to-event analyses. Therefore, it does not meet the criterion of having a primary or key secondary time-to-event efficacy endpoint.待处理
Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non-Small Cell Lung Cancer.Cancer JPMID 35333492PMC89741852022 Mar0.85The record describes a health-related quality-of-life (HRQoL) sub-study or analysis of the Phase III RATIONALE 304 trial. The endpoints are patient-reported outcomes (mean score changes, time to deterioration in QoL), not the required primary or key secondary time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR) for the main trial. Therefore, it is excluded as a 'quality_of_life' report.待处理
Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3).Mod RheumatolPMID 34910203无 PMCID2022-Feb-280.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of a New Sustained-release Pregabalin Formulation Compared With Immediate-release Pregabalin in Patients With Peripheral Neuropathic Pain: A Randomized Noninferiority Phase 3 Trial.Clin J PainPMID 35220330PMC89940392022-Feb-280.98未发现恶性肿瘤人群证据。待处理
Effects of veverimer on serum bicarbonate and physical function in women with chronic kidney disease and metabolic acidosis: a subgroup analysis from a randomised, controlled trial.BMC NephrolPMID 35216581PMC88818242022-Feb-250.98未发现恶性肿瘤人群证据。待处理
Different gut microbial communities correlate with efficacy of albendazole-ivermectin against soil-transmitted helminthiases.Nat CommunPMID 35217670PMC88816082022-Feb-250.98未发现恶性肿瘤人群证据。待处理
Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE).VaccinePMID 35039194无 PMCID2022-Feb-230.98未发现恶性肿瘤人群证据。待处理
Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial.JAMAPMID 35191924PMC88645082022-Feb-220.98未发现恶性肿瘤人群证据。待处理
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.LancetPMID 35085502无 PMCID2022-Feb-190.98未发现恶性肿瘤人群证据。待处理
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.LancetPMID 35085503无 PMCID2022-Feb-190.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension.PlateletsPMID 33586606无 PMCID2022-Feb-170.98未发现恶性肿瘤人群证据。待处理
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.N Engl J MedPMID 34891224无 PMCID2022-Feb-170.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.N Engl J MedPMID 34904798无 PMCID2022-Feb-170.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Long-term Efficacy and Safety of Liquid AbobotulinumtoxinA Formulation for Moderate-to-Severe Glabellar Lines: A Phase III, Double-Blind, Randomized, Placebo-Controlled and Open-Label Study.Aesthet Surg JPMID 34472596PMC88449792022-Feb-150.98未发现恶性肿瘤人群证据。待处理
Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002).Clin Cancer ResPMID 34810217PMC93777632022-Feb-150.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial).Sci RepPMID 35169169PMC88473512022-Feb-150.98未发现恶性肿瘤人群证据。待处理
The efficacy of a suppository based on Phenolmicin P3 and Bosexil (Mictalase®) in control of irritative symptoms in patients undergoing thulium laser enucleation of prostate: a single-center, randomized, controlled, open label, phase III study.BMC UrolPMID 35151280PMC88405492022-Feb-120.98未发现恶性肿瘤人群证据。待处理
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.BloodPMID 34289038PMC88324742022-Feb-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.J Clin OncolPMID 34890214PMC88243932022-Feb-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).J Clin OncolPMID 34905388无 PMCID2022-Feb-101.00命中用户提供的消化道肿瘤阳性参考集。待处理
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.N Engl J MedPMID 34910859PMC86936922022-Feb-100.98未发现恶性肿瘤人群证据。待处理
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.N Engl J MedPMID 34914868PMC86936882022-Feb-100.98未发现恶性肿瘤人群证据。待处理
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.Eur Heart JPMID 35023547PMC88305272022-Feb-100.98未发现恶性肿瘤人群证据。待处理
Survival with Cemiplimab in Recurrent Cervical Cancer.N Engl J MedPMID 35139273无 PMCID2022-Feb-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients.J Headache PainPMID 35139816PMC89035362022-Feb-090.98未发现恶性肿瘤人群证据。待处理
Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.CirculationPMID 34775784PMC88124302022-Feb-080.98未发现恶性肿瘤人群证据。待处理
Referral decisions based on a pre-hospital HEART score in suspected non-ST-elevation acute coronary syndrome: final results of the FamouS Triage study.Eur Heart J Acute Cardiovasc CarePMID 34849660PMC88268402022-Feb-080.98未发现恶性肿瘤人群证据。待处理
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.JAMAPMID 35133415PMC88261792022-Feb-080.98未发现恶性肿瘤人群证据。待处理